WO2003013457A1 - Non-endocrine disrupting cytoprotective uv radiation resistant substance - Google Patents
Non-endocrine disrupting cytoprotective uv radiation resistant substance Download PDFInfo
- Publication number
- WO2003013457A1 WO2003013457A1 PCT/US2002/024866 US0224866W WO03013457A1 WO 2003013457 A1 WO2003013457 A1 WO 2003013457A1 US 0224866 W US0224866 W US 0224866W WO 03013457 A1 WO03013457 A1 WO 03013457A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- sun
- block
- agents
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
Definitions
- This invention relates to new and useful ultraviolet radiation protective agents that can be used as beneficial sun-blocks and in a specific instance sunscreens in various compositions or formulations.
- the compositions include enhanced protection and increased immuno-responsiveness by providing cytoprotective additives for mammalian skin while also providing avoidance from endocrine disrupting agents. It has been determined as of My 2001, that sunscreen agents used in almost all currently marketed and sold ultraviolet protective compositions are essentially void of any cytoprotective agents and contain suspected or documented endocrine disruptive additives.
- UV-B region Ultraviolet radiation of wavelengths between about 290 nm and 320 nm (UV-B region) has been known to rapidly produce damaging effects on the skin including reddening or erythema, edema, blistering or other skin eruptions in more severe cases. Prolonged or chronic exposure to radiation in this wavelength range has been associated with serious skin conditions such as actinic keratoses and carcinomas. In recent years, concern has also been expressed regarding ultraviolet radiation of wavelengths above 320 nm (UV-A region) and the adverse effects of such radiation on human skin.
- the radiation between 320 and 400 nm also contributes to the premature aging of the skin.
- recent studies indicate that chronic sun exposure limits the immuno-response of the skin.
- a tan will offer some protection against burning but that the tan is quite ineffectual against many other types of solar damage and there is no evidence that a tan increases immuno-responsive function in human skin.
- Growing public awareness that the enjoyment of outdoor activities includes the need for adequate sun protection has led to an unprecedented growth in the area of sun-block and sunscreen products.
- UV protective product that has the following attributes: protection in the UV-A and UV-B long range and short range ultraviolet radiation ranges; maintenance of coverage, i.e., waterproof and perspiration proof; application and use convenience, i.e., ease of application, invisibility, non-staining and non-greasy; and freedom from irritation as a result of its ingredients, in particular, its active sun-block or sunscreen ingredients should also be void of any known or suspected endocrine disrupters. Recent interest in this area includes some concerns over the irritancy and sensitization problems in addition to the endocrine disruptive nature that may occur in some individuals utilizing sunscreen products with high SPF values containing organic sunscreen agents.
- the UV protective product could also include known cytoprotective oligosaccharides from aloe barbadensis Miller preventing damage to the skin immune system caused by harmful UV radiation.
- "Cold-pressed" Aloe which contains the beneficial oligosaccharides and provides an emollient base for the UV protective formulation is possibly the best known choice as a cytoprotective agent that inhibits the loss of skin immunocompetency induced by ultraviolet radiation, as this agent is readily available and comparably inexpensive.
- amino-acids vitamins or pro-vitamins, nucleo- derivatives, and vegetable extracts, wherein said aminoacids comprise tryptophan, histidine, phenylalanine, tyrosine
- said vitamins and provitamins comprise vitamin B6, vitamin A, vitamin E, tocopherols, betacarotene, bioflavonoids, nucleotides and polymers thereof, cascara, frangula, camomile, hyperic, calendula, elicriso, licorice or essential oils thereof all may have similar cytoprotective or immune boosting effects on mammalian skin.
- the essential oils of frankincense and rosemary have been found to work effectively and synergistically in strengthening the neuromuscular response of patients who are exposed to its scent in combination with compositions of the present invention.
- the sun protection factor is the ratio of the amount of exposure (dose) required to produce a minimal erythema reaction in protected skin to the amount required to produce the same reaction in unprotected skin.
- the absolute dose differs for each human and for each mammal, and is largely dependent on genetic predisposition and ethnic origin of the human. If a human or other mammal would normally require ten- minute exposure to sunlight to develop a minimal erythema reaction, then using an SPF 15 sun-block should allow for tolerance of up to 150 minutes of sunlight before developing a minimal erythema. Relatively recent public awareness of the problems of exposure to sunlight has led to a demand for sun-block products with high SPF values, i.e., at or above SPF 8.
- the immuno-response rating system could be a simple 0-10 value, with 10 applying to a substance within the UV-protective composition that is most beneficial to boosting skin cell immune responsiveness to carcinoma, melanoma, etc. (for instance).
- Endocrines are essentially excretions from organs or glands.
- the organs or glands continually function by discharging waste or at the least exchanging fluids from an inlet side to an outlet side. Any disruption in the natural behavior of an organ or gland could have a deleterious effect on the ability of that organ or gland to continue to function normally.
- a UV-protective formulation or composition that may inhibit normal endocrine function(s) is at least undesirable, and at most a potential health threat to millions who continue to apply such a formulation or composition directly to their skin.
- SPF value may be high
- the potential for endocrine disruption may also be high and again this poses the possibility of another ranking system.
- the 0-10 rating has appeal, with 0 being the desired criteria that a consumer would want to purchase to ensure consumption of a quality product that is also completely safe in terms of potential adverse health effects.
- NED Non-endocrine disrupter factor
- the ultimate UV-protective formulation would safely block or screen UV light, enhance the immune responsiveness of the skin in the absence or presence of UV, and ensure the user that there is no endocrine disrupting substance present.
- Ease of application and cosmetic appeal are important in formulating sun protective compositions. These characteristics rely on subjective evaluations such as visual and tactile impression by the user. Softening compounds such as emollients provide an excellent basis for a soothing compound to add to the cosmetic appeal, so long as those emollients used don't contain endocrine disrupting agents.
- One emollient of the present invention is cold processed aloe. Consumer research studies indicate that a sunblock formulation should rub in easily, leave the skin non-sticky and, above all should be invisible on the skin after application. Sun protective compositions containing organic sunscreen agents have been found, in some cases, to irritate the skin.
- endocrine disrupting agents exist in currently available sunscreen formulations including; benzophenone-s, homosalate, 4-methyl- benzylidene camphor, octyl methoxycinnamate, and octyl-dimethyl-PABA. All of these substances, in fact, made cancer cells grow more rapidly and three caused developmental effects in animals. Therefore a non-endocrine disrupting UV protective formulation should include the use of inorganic sun-block agents, such as titanium dioxide and/or zinc oxide.
- a recent development in the reduction of particle sizes of ZnO has resulted in micro-fine, essentially clear ZnO, when applied to the skin.
- Z-Cote which is a trademarked composition sold by BASF.
- Z-Cote is a trademarked composition sold by BASF.
- the need for an acceptable emollient that reduces the negative affects associated with abrasive inorganics and that also includes the benefit of providing cytoprotection and healing of the skin is necessary. Allowing for the reduction of irritation or sensitization of the skin suggests that "cold-pressed" Aloe is a useful and necessary ingredient for such a UV-protective formulation.
- Japanese Patent Application No. 1981-161, 881 describes cosmetics containing 0.1-40% of ultrafine divided titanium oxide with a particle size of 10-30 nm which has been rendered hydrophobic. It indicates that when hydrophobically treated titanium dioxide with a particle size of 10-30 nm is blended into cosmetic base materials, it transmits visible light but reflects and scatters the harmful ultraviolet rays. It has been found that when these titanium dioxide compositions are utilized as a sun-block agent in sun-block compositions, it may result in the loss of one of the most desired properties of such compositions, i.e., invisibility.
- USP No. 5340567 issued August 23, 1994 describes a sun-block composition comprising a synergistic combination of titanium dioxide having a particle size of less than about 35 nm and zinc oxide having a particle size of less than about 50 nm with titanium dioxide and zinc oxide being present at given ratios.
- German Patent No. 3642794(1987) describes a cosmetic composition for preventing sunburn which contains 1-25% zinc oxide of a particle size of 70-300 microns. It further indicates that the composition may also contain titanium dioxide of a particle size of 30- 70 microns. This composition is undesirably due to its unaesthetic whiteness characteristics at high SPF levels.
- World Patent Application WO 90/06103 published June 14, 1990, describes titanium dioxide sun-block where the microfine titanium dioxide particles are coated with a phospholipid, either through the use of a powder mill or through the making of a dispersion in an oil phase containing the phospholipid with a high shear mixer.
- the phospholipid coated titanium dioxide is the incorporated into sun-block compositions.
- a high efficiency is claimed: the data presented shows SPF values of up to 11 for a 3.75% titanium dioxide concentration and up to 25 for a for a 7.5% concentration of titanium dioxide.
- the use of high shear mixer or a powder mill is complicated and energy intensive process.
- EP 535372 Al published April 7, 1993 describes a method of preparing sun-block in which a dispersion of zinc oxide and/or titanium dioxide particles in an oil are formed by milling.
- EP 619999 A2 published October 19, 1994 describes an aqueous dispersion of particulate metallic oxide of particle size less than 200 nm mixed with an emulsifier and an oil phase and also an organic hydrophobic sunscreen to form an o/w emulsion.
- the resulting sun protection composition has a higher SPF than would be expected if there was only an additive effect.
- the titanium dioxide alone at 4 % yielded a SPF of only 7 to about 11.
- EP 628303 published October 19, 1994 describes a process for preparing a sun-block composition. It consists of mixing sun-block particles of metallic oxide less than 200 nm dispersed in an oil with one or more emulsifier and/or organic sun-block. The resulting sun-block composition is claimed to have a SPF value considerably higher than expected. The high SPF is only obtained when a metallic oxide is blended with an organic sunblock. In fact, when no organic sun-block is used, the SPF value is only about 7.
- WO 93/11742 describes sun-block compositions comprising titanium dioxide and iron oxide of particle size less than 200 nm preferably coated with a phospholipid.
- USP No. 5498406 describes sun-block compositions in an oil-in-water emulsion containing both organic and inorganic sun protective ingredients and comprising long chain (C25-45) alcohols for stabilization of the emulsion.
- This composition relies predominately on the organic sunscreen active components. While the authors mention the use of stearic acid as a part of the oil in water composition, they teach against the use of stearic acid in stabilizing the titanium dioxide with C 22-45 alcohols.
- USP No. 6099825 describes sun-block having disappearing color which is extremely useful when combined with titanium dioxide or zinc oxide. It was unexpectedly found that although the inclusion of particulate pigments in a sun-block emulsion can render the sun-block visually colored as it is being spread onto the skin and that the coloration will substantially disappear when the sun-block emulsion is rubbed into the skin.
- USP 6042813 also describes sun-block having disappearing color indicator.
- the sunblock includes at least one active sun-block agent, at least one emulsifier, sufficient amounts of water to create the colored emulsion, and at least one oil-soluble dye that imparts color to the emulsion.
- USP No. 6048517 issued April 11, 2000, describes low-cost sunscreen compositions with high SPF values of at least 40.
- the ingredients in the sunscreen include mixtures of homosalate, octyl salicylate, oxybenzone, octyl methoxycinnamate, or avobenzone.
- USP No. 5770183 issued June 23, 1998, describes an emulsion that contains a water phase and an oil phase that includes active sun-block ingredients and skin conditioning agents.
- the sun-block provides an SPF greater than 30, and the particle size in the oil phase averages 2.0 microns, providing high levels of protection from the sun while using minimum amounts of active sun-block agents.
- WO 99/11236 published first in Germany and then as a WO document dated March 11, 1999, describes a transparent sun-block gel that contains methlyvinyl ether and maleic acid copolymers cross-linked with decadiene.
- EP 0834301 published March 8, 1998, describes compositions that include glutathione liposomes combined with at least one emulsifier and are topically applied to the skin to prevent the damaging effects of UV radiation.
- USP 5980871 issued November 9, 1999 to Johnson and Johnson, and apparently licensed to Neutrogena, describes a sun-block composition that includes inorganic sunblock agents, such as titanium dioxide or zinc oxide, anionic emulsifiers, and an oil component.
- the composition allows for SPF greater than 10 with a titanium dioxide concentration of about 4%.
- This USP 5980871 further describes the method required to make the sun-block.
- compositions and methods most closely resembles the present invention. There is no mention, however, of the use of any cytoprotective agents or the importance of providing only non-endocrine disruptive agents to the composition. In our review of commercially available products, this composition would appear to pose the least risk in terms of both short and longer-term health effects. The product itself, however, is somewhat undesirable as it leaves a very white appearance on the skin for long periods of time, is difficult to spread, and somewhat abrasive to sensitive skin. In addition, the composition allows for the use of parabens as inactive ingredients, also recently found to be suspected endocrine disrupters as cited in the reference EPA website as an appendage to this specification.
- the present invention is directed toward a colored sunblock emulsion
- a colored sunblock emulsion comprising: (a) at least one ultramarine pigment that imparts a color other than white to the emulsion with a titanium dioxide or zinc oxide or possibly fumed or fused silica or even silicon dioxide so that when the emulsion is rubbed into the skin, the color substantially disappears; (b) at least one sun-block active agent in an amount effective to protect skin against the actinic radiation of the sun - this preferably being ZnO or Z-Cote; (c) no known or suspected endocrine disrupting organic substances; (d) a cytoprotective substance such as a glucose-rich mannose-containing oligosaccharide obtained from and used with aloe barbadensis Miller as the at least one emulsifier; and (e) sufficient water to form the other than a white colored emulsion.
- the amount of the ultramarine pigment in the composition can range form about 0.5 to about 10 weight percent of the composition, preferably form about 1 to about 5 weight percent of the final formulation. This pigment is for cosmetic appeal only and is not required in the present invention.
- the colored sun-block emulsion can contain one or more additional ingredients, including emollients, waterproofing agents, dry-feel modifiers, insect repellants, antimicrobial preservatives and/or fragrances.
- the present invention is directed towards a method for protecting the skin against sunburn while increasing mammalian skin cell immunoresponse to cancerous skin cells while eliminating possible endocrine disruption response of human organs comprising topically applying the sun-block formulation as described above to the skin.
- An advantage of the present invention is that it provides a sun-block and a method for protecting against sunburn that enables the user to apply the sun-block more completely and uniformly to the skin, thus providing more effective protection against skin damage and homogenously enhancing cytoprotection while eliminating endocrine disruptive organics, thus providing for long term health and safety in the presence of UV light.
- Another advantage of the present invention is that it provides a sun-block with a color indicator which has a low fabric staining potential, and for which those stains that form can easily be removed from fabrics.
- Still yet another advantage of the present invention is that it provides an optionally colored sun-block and a method for protecting against sunburn that is more enjoyable for human use because of the attractiveness and appealing nature of the color indicator. For domesticated animals, the use of matching colors may also be appealing.
- the invention allows for the use of ultrafine ZnO particles that are invisible when applied to human skin. This "invisible” ZnO would be the primary and perhaps only sun-block "active" ingredient.
- Another object of this invention addresses the potential risks and disadvantages, provides a viable and economically attractive alternative to the present commercial market, and proposes a new and safer rating system to rank sun protection products for the consumer.
- sun-blocking compositions containing inorganic sun-blocking agents or known non-endocrine disruptive sun-block agents as the active ingredients. More particularly, the present invention relates to sun-blocking compositions containing zinc oxide and, optionally, titanium dioxide of preferred particle size ranges, and in preferred amounts and ratios. These sun-blocking agents together with specifically cold- pressed aloe that contains an oligosaccharide of molecular weight of approximately 1- 5,000 daltons that is glucose rich and also contains mannose which inhibits the loss of skin immuno-competency form the basis of a novel protective UV formulation.
- compositions permit the use of much lower amounts of the sun-block active ingredients than previously achievable while still achieving desired and very high SPF values for the compositions and without the unsightly whiteness which occurs in prior sun-block compositions at concentrations above about 5%.
- concentrations of zinc oxide and possibly titanium dioxide may also be used without incurring a whitening effect, e.g., even up to 15% with acceptable appearance, or possibly higher.
- our invention does not rely upon the use of hydrophilic titanium dioxide preparations as required in the above noted patents, nor are energy intensive processes such as powder milling, nor are organic active sun-block required for high efficacy.
- a method of mixing either zinc or titanium dioxide with cold processed aloe initially, before mixing any of the other ingredients for the sun-block is an embodiment of the present invention.
- the purpose of this primary mixing step is that wetting of the oxide is necessary and important and occurs well in combination with the aloe.
- compositions of this invention are primarily oil-in-water emulsions containing at least the following components:
- an optional oil component comprising a carrier oil, preferably an essential oil any of which are also non-endocrine disruptive and immuno-enhancing and;
- at least one emollient where said emollient may be the cytoprotective emulsifier of (b) above.
- An emollient is preferably aloe as it is "Cold processed” or an extract of aloe that is currently removed during normal processing and recovered by some means.
- the aloe or its extract may not provide sufficient emulsification based on the remaining ingredients of the composition.
- compositions of this invention provide formulations having an SPF of at least 10 with a concentration level of titanium dioxide of about 4% .
- the compositions of this invention exhibit extremely efficient uses of sun-block components, particularly zinc oxide.
- the compositions of this invention therefore may be formulated so as to contain relatively smaller amounts of zinc oxide than used heretofore at a given SPF level.
- higher levels of titanium dioxide or zinc oxide can be used if ultramarine pigments are added to the composition.
- These pigments are known to eliminate the whiteness and poor spreadability of currently available compositions. For the purposes of this invention, however, these pigments must be known to be non-endocrine disruptive as well as to not interfere with the cytoprotective influence of the oligosaccharide aloe extract.
- compositions of this invention are easily made by simple mixing and provide an excellent dispersion of the inorganic based sun-block/sunscreen agent throughout the composition, thus ensuring even skin coverage.
- the compositions are substantially invisible upon application to the skin.
- the embodiments of the present invention include three main characteristics required for any and all agents, which must be either one of or all of: a known non-endocrine disrupting agent; an immuno-enhancing agent; and a cytoprotective agent.
- a combination of agents containing all the above properties is an embodiment of the present invention, and all compounds fitting within the above characteristics are part of the same inventive entity.
- the ultimate sun-block composition of the present invention must have at least one cytoprotective agent and no endocrine disrupting agents.
- the present invention will include at least one immuno-enhancing agent if such cytoprotective agent is not itself an immuno-enhancing agent.
- Such a compound may also be a sunscreen and not simply a sun-block.
- a sunscreen acts as a filter to certain UV rays, while a sun-block acts as a complete barrier to those UV rays.
- Such a sunscreen agent in keeping with the inventive concepts of the present invention, must also exhibit only non-endocrine disrupting agents. Only one known organic UVA protector, butyl-methoxydibenzoyhnethane has been shown to be benign regarding activity in cells or developmental effects on animals. This compound is of the type to act as such a sunscreen for the purposes of the present invention. DETAILED DESCRIPTION OF THE INVENTION
- the UV-protective compositions of this invention yield highly effective ultraviolet (UV) blocking capabilities.
- a given level of protection may be provided with a significantly lower concentration of either zinc oxide or titanium dioxide than previously obtained using commercially available powdered titanium dioxides. They do not require the unusual processing methods previously necessary to disperse the titanium dioxide into an oil, such as preparation of sub-batch mill bases, high shear mixing or milling, or applying such milling procedures to the final product formulation.
- a typical titanium dioxide sunblock composition of SPF 15 requires levels of titanium dioxide that impart a significant whitening effect to the skin; the compositions of this invention, minimize this disadvantage and are therefore economically viable to produce.
- compositions of this invention are primarily oil-in-water emulsions that are cosmetically superior to conventional inorganic preparations, including water-in-oil titanium dioxide and zinc oxide-only formulations, at equivalent SPF ratings, due to the low levels of both oxides needed in the invention system.
- the compositions of this invention can be used for sun protection in daily wear or facial products as well as for recreational situations. Because of the efficiency of the system, the inventive formulations are significantly lower in cost than other sun-block or sunscreen systems.
- the actual UV protective formulation will vary based on the environmental location, length of exposure, age, health and other factors involving individual mammals, such that the concentrations of non-endocrine disruptive UVA screens, UVB screens, inorganic pigments, and cytoprotective agents will vary.
- compositions of this invention may by necessity include one or more of a select group of anionic emulsifiers.
- salts of certain fatty acids are useful in the formulations of this invention, preferably salts of saturated fatty acids and/or salts of straight-chain fatty acids.
- Alkali metal salts, alkali earth metal salts and amine salts are more preferable for use in the compositions of this invention.
- stearic acid and its salts are useful as emulsifiers in the compositions of this invention, while the use of isostearate salts tends to produce a composition which is not very efficient in the use of sun-block.
- oleate salts are not useful as they are unsaturated and do not result in efficient sun-block compositions.
- anionic emulsifiers are useful in the compositions of this invention: sodium stearate, sodium lauryl sulfate, DEA cetyl phosphate, sodium dioctyl sulfosuccinate and the like. Most preferably, the emulsifier should be sodium stearate. While it is not fully understood why some salts of fatty acids result in an inventive composition, it is theorized that salts of straight-chain fatty acids, (the fatty acids having a relatively high melting point, above 70 'C. or higher), are preferable due to their structure. For example, salts of branched or unsaturated fatty acids are most likely not acceptable for use in the compositions of this invention.
- the anionic emulsifiers should be present in the compositions of this invention in an amount from about 0.01 to about 10% , more preferably 0.1 to about 7% and most preferably from about 0.5 to about 5%.
- additional emulsifiers present in the compositions of this invention, such as nonionic emulsifiers known to those of ordinary skill in the art such as sorbitan esters and ethoxylated sorbitan esters, ethoxylated fatty acids, fatty alcohols and ethoxylated fatty alcohol's, fatty glyceride esters and ethoxylated fatty glyceride esters and the like.
- amonic emulsifier there may have to be at least one amonic emulsifier present in order to achieve the products of this invention.
- the fatty acid salt emulsifiers may be added to the composition as the salts, or the salt may be formed in situ. In all cases, these additives would only be present if they are found to be endocrine disruption free and non-deleterious to any inhibition of skin immuno-competency.
- a carrier oil may also be required in the compositions of this invention. It may be selected from the group of essential oils that are not known or suspected non-endocrine disrupters.
- carrier oil could be a C8 to C22 fatty alkyl (optionally polypropylenoxy) polyethylenoxy carboxylate ester, the ester having an alkyl group which has from on to twenty-two carbon atoms, optionally straight or branched or can contain a phenyl group.
- the carrier oil should be isopropyl PPG-2 isodeceth-7 carboxylate, such as Velsan D8P3 or other commercially available materials sold by Clariant under the Velsan trade name.
- Other similar structures include Hetester PHA available from Bernel. All such oils must be proven to be non-endocrine disrupters and to not interfere with the inhibition of skin immuno-competency.
- the carrier oil which is more preferably an essential oil, should be present in the composition in an amount of between about 0.1% and about 10%. More preferably, it should be present in the amount of between about 1% and about 5%. Most preferably, it should be present in the amount of between about 2% and about 3%.
- the oil phase should contain at least two materials, the carrier oil or essential oil and a conventional emollient known to those of ordinary skill in the art as useful in sun-block products, such as vegetable oils, silicones, synthetic emollients such as fatty acid esters and the like.
- the use of a Cold processed aloe barbadensis Miller is to be substituted as an emollient or can be used in combination with the oils or synthetic emollients that are proven to be non-endocrine disrupting as well as not interfering with augmenting the cytoprotective enhancing effects of the known effective oligosaccharide aloe extract.
- the emollient should be present in the formulation in a ratio to the carrier concentration of from about 1:1 to about 3:1, most preferably, about 2:1.
- the carrier oil and the emollient should compose from about 2% to about 20% of the total composition weight.
- a third element which should be present in the compositions of this invention is an inorganic sun-block compound, such as titanium dioxide, zinc oxide or combinations thereof.
- Possible other inorganics include the use of fused or fumed silica or even silicon dioxide.
- zinc oxide should be used having a primary particle size from of less than about 300 nm in diameter. It should be present in the composition in the amount of from about 2% to about 25%. More preferably, it should be present in the amount of from about 2% to about 15%. Most preferably, it should be present in the amount of from about 3% to about 10%.
- the inorganic sun-block compound should be oil dispersible, and may be present with or without surface coating.
- the ratio of titanium dioxide or zinc oxide to the weight of the carrier oil and the emollient combined should be from about 0.3:1 to about 1:1. Most preferably, the ratio should be between about 0.5:1 and 2:3.
- the usual elements of a modern sun-block emulsion system may be necessary such as a polymeric thickener/stabilizer, one or more additional emollient oils, microbial preservations, waterproofing agents, antioxidants, fragrance, humectant, and of course the water vehicle may all utilized using careful selection or restraint based on the constraints of providing a non-endocrine disrupting immuno-enhancing composition.
- the base formulation of this invention may also be used as carrier compositions for active topical agents having dermatological effects, including depigmentation agents, anti-aging ingredients, antifungal agents, antimicrobial agents, insect repellents and the like.
- depigmentation agents can include magnesium ascorbyl phosphate or hydroquinone but only used in the final composition if these agents are shown not to be endocrine disrupters.
- Anti-aging agents can include retinoid compounds and alpha- hydroxy acids again only if these agents are shown not to be endocrine disrupters.
- Anti- fungal agents that can be included in the compositions of this invention include azole compounds including ketoconazole and the like again only if these agents are shown not to be endocrine disrupters.
- Anti-microbial agents include triclosan, an unknown agent regarding cyto-toxicity or endocrine disruption function.
- Insect repellant fragrances can be included in the compositions of this invention again only if these agents are shown not to be endocrine disrupters or cytotoxic.
- Other agents and ingredients known to those of ordinary skill in the art that may be delivered to the skin without providing known or suspected endocrine disruptive or cytotoxic properties should be considered as compositions of this invention.
- compositions of this invention would then have minimally a multi-action capability, as they would contain both sun-block agents and other actives for protecting, treating, and enhancing the immunoresponsive nature of the skin.
- compositions of this invention can be incorporated into various cosmetic and personal care products such as hand and body lotions, oils, ointments, lip balm products, facial cosmetics and the like.
- the sun-block compositions of this invention may be prepared using one of at least two methods: a two- vessel method, in which the oil and water phases are individually prepared, and a one-vessel method into which all ingredients are added in selected specific order. Any of these processes will produce a smooth uniform, white to light ivory emulsion. When combined with ultramarine pigments, the color will change and also provide a clear appearance as the composition is applied to the skin.
- a water phase is prepared by measuring deionized water into a beaker and mixing.
- the elements of the water phase including emulsifiers and humectants, chelators, thickeners, waterproofing agents, neutralizing agents and antioxidants should be added and the solution heated. If an anionic emulsifier is used it may be placed into the water phase or into the oil phase, depending upon the nature of the emulsifier.
- the oil phase is prepared separately in another vessel, including the anionic emulsifier, carrier oil, emollient and inorganic sun-block agent. The two phases are then held at a relatively high temperature and mixed.
- the water and oil phases may be made in the same vessel, provided that the components are added in an appropriate order.
- the water phase should be created first, adding water and optionally certain emulsifiers which are compatible with the water phase to the vessel.
- the vessels should be heated to about 85 C to about 95C.
- the oil phase components may be added, including, optionally, anionic emulsifiers if they are oil phase compatible and the carrier oil, as well as any additional oil-phase emulsifiers, antioxidants and/or emollients that maybe desired.
- the temperature should be maintained at this level for about 15 minutes, and the inorganic sun-block agent added slowly, and the composition mixed for a period of time of at least about 30 minutes.
- Essential oils may be added later in very small amounts to provide fragrance of most any naturally occurring plant, crop, fruit, or nut.
- the essential oils are often obtained by simple distillation. It has been shown that the aroma of the essential oils in the proper combination with the sun-block or sunscreen of the present invention should provide strengthening of the neuromuscular system. This is believed to also provide an enhancement of the immuno-enhancing properties of the present invention.
- pages 16 a-d contain all referenced material which are incorporated herewithin and have been used to describe this invention.
- Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on f- the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 202 3 1. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
- EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not In conformance and not considered. Include copy of this form with next communication to applicant.
- Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
- EXAMINER Initial if reference considered, whether or not citation Is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
- Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
- EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not In conformance and not considered. Include copy of this form with next communication to applicant.
- Burden Hour Statement This form Is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on t- the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/485,989 US20060233725A1 (en) | 2001-08-09 | 2002-08-08 | Non-Endocrine Disrupting Cytoprotective UV Radiation Resistant Substance |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/682,249 | 2001-08-09 | ||
US09/682,249 US6866841B2 (en) | 2001-08-09 | 2001-08-09 | Non-endocrine disrupting cytoprotective UV radiation resistant substance |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003013457A1 true WO2003013457A1 (en) | 2003-02-20 |
Family
ID=24738874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/024866 WO2003013457A1 (en) | 2001-08-09 | 2002-08-08 | Non-endocrine disrupting cytoprotective uv radiation resistant substance |
Country Status (2)
Country | Link |
---|---|
US (3) | US6866841B2 (en) |
WO (1) | WO2003013457A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1297478C (en) * | 2003-11-28 | 2007-01-31 | 上海家化联合股份有限公司 | Molecular sieve based nano composite anti-ultraviolet material, its preparation method and use |
US20080219939A1 (en) * | 2007-03-07 | 2008-09-11 | Grune Guerry L | Sunblock formulations |
US20080219938A1 (en) * | 2007-03-07 | 2008-09-11 | Grune Guerry L | SPF compositions |
US20100028276A1 (en) * | 2007-03-05 | 2010-02-04 | Grune Guerry L | Sunscreen compositions |
US20150110724A1 (en) * | 2006-05-26 | 2015-04-23 | Guerry L. Grune | High SPF Transparent or Translucent Naturally Derived, Cytoprotective, UV Radiation Resistant Compositions |
US9095522B2 (en) * | 2007-03-19 | 2015-08-04 | Guerry L. Grune | High SPF transparent or translucent, cytoprotective, biodegradable, UV radiation resistant compositions |
EP2501777B1 (en) * | 2009-11-20 | 2022-10-26 | Guerry L. Grune | Broad spectrum uva stable, non-toxic, zinc oxide based complex |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6866841B2 (en) * | 2001-08-09 | 2005-03-15 | Epatentmanager.Com | Non-endocrine disrupting cytoprotective UV radiation resistant substance |
US20060292094A1 (en) * | 2005-06-24 | 2006-12-28 | Robert Bell | Composition and method of protection against UV irradiation |
WO2007136881A2 (en) * | 2006-05-24 | 2007-11-29 | Grune Guerry L | Non-endocrine disrupting, cytoprotective, uv radiation resistant sunblock compositions |
WO2008136889A1 (en) * | 2007-03-07 | 2008-11-13 | Grune Guerry L | High spf transparent or translucent, cytoprotective, biodegradable, uv radiation resistant compositions |
US8216555B2 (en) * | 2008-02-13 | 2012-07-10 | Bart Willem Nieuwenhuijsen | Composition of a water-soluble sunscreen preparation for acne rosacea |
US8337820B2 (en) * | 2008-02-13 | 2012-12-25 | Bart Nieuwenhuijsen | Composition of a water-soluble sunscreen preparation for acne rosacea |
US20090269375A1 (en) * | 2008-04-25 | 2009-10-29 | Diahne Patnode | Tanning compositions containing juice concentrate |
FR2940615B1 (en) * | 2008-12-30 | 2011-12-30 | Oreal | ASSOCIATION OF MONOSACCHARIDES WITH ANTIOXIDANT AGENTS AND ITS USE IN COSMETICS |
FR2940613B1 (en) * | 2008-12-30 | 2012-09-21 | Oreal | ASSOCIATION OF MONOSACCHARIDES WITH SOLAR FILTERS AND ITS USE IN COSMETICS |
FR2940609B1 (en) * | 2008-12-30 | 2011-05-06 | Oreal | ASSOCIATION OF MONOSACCHARIDES AND DESQUAMANT AGENTS AND USE THEREOF IN COSMETICS |
FR2940612B1 (en) * | 2008-12-30 | 2011-05-06 | Oreal | ASSOCIATION OF MONOSACCHARIDES WITH ASCORBIC ACID AND ITS USE IN COSMETICS |
CN103830123A (en) * | 2013-10-02 | 2014-06-04 | 铁生年 | Sunscreen cream containing microsilicon powder |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2157562A (en) * | 1984-04-17 | 1985-10-30 | Oreal | Cosmetic composition containing aloesin as an agent for protection against sunlight and its use for skin and hair protection |
EP0497144A1 (en) * | 1991-01-16 | 1992-08-05 | Estee Lauder Inc. | Styrene-ethylene-propylene copolymer containing cosmetic compositions and their use |
US5356811A (en) * | 1992-04-21 | 1994-10-18 | Coats Billy C | Method of processing stabilized aloe vera gel obtained from the whole aloe vera leaf |
US5587150A (en) * | 1990-02-14 | 1996-12-24 | L'oreal | Photostable cosmetic screening composition containing a UV-A screening agent and an alkyl β, β-diphenylacrylate or α-cyano-β,β-diphenylacrylate |
WO1996041614A1 (en) * | 1995-06-08 | 1996-12-27 | Johnson & Johnson Consumer Products, Inc. | Sunscreen compositions |
US5618520A (en) * | 1992-09-17 | 1997-04-08 | L'oreal | Photostable filtering cosmetic composition containing a UV-A filter and a filtering polymer of the benzotriazole silcone type |
US5824659A (en) * | 1996-09-04 | 1998-10-20 | Board Of Regents, The University Of Texas System | Cytoprotective oligosaccharide from Aloe preventing damage to the skin immune system by UV radiation |
WO1999024000A2 (en) * | 1997-11-12 | 1999-05-20 | Merck Patent Gmbh | Light stable cosmetic formulation containing butylmethoxydibenzoylmethane |
WO1999024006A1 (en) * | 1997-11-12 | 1999-05-20 | Merck Patent Gmbh | Stable cosmetic formulation containing butylmethoxydibenzoylmethane |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56161881A (en) | 1980-05-19 | 1981-12-12 | Ebara Infilco Co Ltd | Caking of pulverized waste |
MY100306A (en) | 1985-12-18 | 1990-08-11 | Kao Corp | Anti-suntan cosmetic composition |
US5028417A (en) | 1987-07-20 | 1991-07-02 | Johnson & Johnson Consumer Products, Inc. | Sunscreen compositions |
GB8827968D0 (en) | 1988-11-30 | 1989-01-05 | Boots Co Plc | Sunscreen compositions |
CA2069864A1 (en) * | 1989-12-04 | 1991-06-05 | Rupali A. Kulkarni | Photoprotective compositions |
JPH03279323A (en) | 1989-12-15 | 1991-12-10 | Johnson & Johnson Consumer Prod Inc | Anti-sunburn composition |
US5622690A (en) * | 1990-04-05 | 1997-04-22 | Nurture, Inc. | Seed-derived proteinaceous compositions for reduction of sunburn cell formation |
GB9010526D0 (en) | 1990-05-10 | 1990-07-04 | Unilever Plc | Cosmetic composition |
US5733531A (en) | 1991-02-05 | 1998-03-31 | Sunsmart, Inc. | Composite UV sunblock compositions |
PH31287A (en) | 1991-05-07 | 1998-07-06 | Rihardson Vicks Inc | Photoprotection compositions. |
DE4132579C1 (en) | 1991-09-30 | 1992-12-10 | Siemens Ag, 8000 Muenchen, De | |
GB9126440D0 (en) | 1991-12-12 | 1992-02-12 | Boots Co Plc | Sunscreen compositions |
US5487885A (en) * | 1992-12-21 | 1996-01-30 | Biophysica, Inc. | Sunblocking polymers and their formulation |
US5552135A (en) | 1993-02-25 | 1996-09-03 | Estee Lauder, Inc. | Sunscreens containing plant extracts |
GB9307658D0 (en) | 1993-04-14 | 1993-06-02 | Tioxide Specialties Ltd | Compositions containing sunscreens |
US5643554A (en) * | 1993-04-30 | 1997-07-01 | Dusa Pharmaceuticals, Inc. | Lipomelanim composition |
US5498406A (en) | 1993-04-30 | 1996-03-12 | Nearn; Malcolm R. | Titanium dioxide-based sunscreen compositions |
GB9312045D0 (en) | 1993-06-11 | 1993-07-28 | Tioxide Specialties Ltd | Compositions containing sunscreens |
GB9316901D0 (en) * | 1993-08-13 | 1993-09-29 | Unilever Plc | Sunscreen agents |
US5492690A (en) | 1994-03-03 | 1996-02-20 | The Procter & Gamble Company | Benzoylacetate esters as non-sensitizing chelating photo-protectants |
US5505935A (en) * | 1994-05-09 | 1996-04-09 | Elizabeth Arden Company, Division Of Conopco, Inc. | Sunscreen compositions |
IT1276698B1 (en) | 1995-06-09 | 1997-11-03 | Sa Fo Sa Srl | NATURAL BASED SCREENING AND ANTIERITEMA MIXTURE |
US5565591A (en) * | 1995-06-14 | 1996-10-15 | Sunsmart | Silicone polymers for the modification of titanium dioxide |
US5747010A (en) | 1996-06-12 | 1998-05-05 | Johnson & Johnson Consumer Products, Inc. | Photoprotective lipophilic antioxidant compounds and their use to prevent UVA-mediated lipid peroxidation |
US5770183A (en) | 1996-08-01 | 1998-06-23 | Linares; Francisco J. | High SPF (30 and over) waterproof sunblock compositions |
GB9620504D0 (en) | 1996-10-02 | 1996-11-20 | Boehringer Ingelheim Ltd | Compositions |
US6048517A (en) | 1996-11-25 | 2000-04-11 | Schering-Plough Healthcare Products, Inc. | High SPF sunscreen formulations |
US5747011A (en) * | 1996-11-25 | 1998-05-05 | Schering-Plough Healthcare Products, Inc. | Sunscreen with disappering color indicator |
DE19739447A1 (en) | 1997-09-02 | 1999-03-04 | Coty Bv | Emulsifier-free, clear sunscreen gel |
US5945090A (en) | 1997-09-11 | 1999-08-31 | Randall Products International | Sunscreen preparation |
US5914102A (en) * | 1997-11-26 | 1999-06-22 | Schering-Plough Healthcare Products, Inc. | High SPF perspiration-resistant sunscreen |
US5972362A (en) * | 1997-12-23 | 1999-10-26 | Wenker; Naamah T. | Therapeutic skin preparation |
US6015548A (en) * | 1998-07-10 | 2000-01-18 | Shaklee Corporation | High efficiency skin protection formulation with sunscreen agents and antioxidants |
US5965518A (en) * | 1998-02-23 | 1999-10-12 | Nakatsu; Tetsuo | Fragrance compositions having antimicrobial activity |
US6042813A (en) | 1998-05-04 | 2000-03-28 | Schering-Plough Healthcare Products, Inc. | Sunscreen having disappearing color indicator |
US6083508A (en) * | 1998-05-19 | 2000-07-04 | Avalos; Ramiro Estrada | Method of processing aloe leaves |
US6284234B1 (en) | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
US6099825A (en) | 1999-05-26 | 2000-08-08 | Schering-Plough Healthcare Products, Inc. | Sunscreen having disappearing color |
US6866841B2 (en) * | 2001-08-09 | 2005-03-15 | Epatentmanager.Com | Non-endocrine disrupting cytoprotective UV radiation resistant substance |
WO2006000103A1 (en) | 2004-06-29 | 2006-01-05 | Universite De Sherbrooke | Spiking neural network and use thereof |
-
2001
- 2001-08-09 US US09/682,249 patent/US6866841B2/en not_active Expired - Lifetime
-
2002
- 2002-08-08 US US10/485,989 patent/US20060233725A1/en not_active Abandoned
- 2002-08-08 WO PCT/US2002/024866 patent/WO2003013457A1/en not_active Application Discontinuation
-
2005
- 2005-02-28 US US11/068,567 patent/US20050196361A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2157562A (en) * | 1984-04-17 | 1985-10-30 | Oreal | Cosmetic composition containing aloesin as an agent for protection against sunlight and its use for skin and hair protection |
US5587150A (en) * | 1990-02-14 | 1996-12-24 | L'oreal | Photostable cosmetic screening composition containing a UV-A screening agent and an alkyl β, β-diphenylacrylate or α-cyano-β,β-diphenylacrylate |
EP0497144A1 (en) * | 1991-01-16 | 1992-08-05 | Estee Lauder Inc. | Styrene-ethylene-propylene copolymer containing cosmetic compositions and their use |
US5356811A (en) * | 1992-04-21 | 1994-10-18 | Coats Billy C | Method of processing stabilized aloe vera gel obtained from the whole aloe vera leaf |
US5618520A (en) * | 1992-09-17 | 1997-04-08 | L'oreal | Photostable filtering cosmetic composition containing a UV-A filter and a filtering polymer of the benzotriazole silcone type |
WO1996041614A1 (en) * | 1995-06-08 | 1996-12-27 | Johnson & Johnson Consumer Products, Inc. | Sunscreen compositions |
US5824659A (en) * | 1996-09-04 | 1998-10-20 | Board Of Regents, The University Of Texas System | Cytoprotective oligosaccharide from Aloe preventing damage to the skin immune system by UV radiation |
WO1999024000A2 (en) * | 1997-11-12 | 1999-05-20 | Merck Patent Gmbh | Light stable cosmetic formulation containing butylmethoxydibenzoylmethane |
WO1999024006A1 (en) * | 1997-11-12 | 1999-05-20 | Merck Patent Gmbh | Stable cosmetic formulation containing butylmethoxydibenzoylmethane |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1297478C (en) * | 2003-11-28 | 2007-01-31 | 上海家化联合股份有限公司 | Molecular sieve based nano composite anti-ultraviolet material, its preparation method and use |
US20150110724A1 (en) * | 2006-05-26 | 2015-04-23 | Guerry L. Grune | High SPF Transparent or Translucent Naturally Derived, Cytoprotective, UV Radiation Resistant Compositions |
US20100028276A1 (en) * | 2007-03-05 | 2010-02-04 | Grune Guerry L | Sunscreen compositions |
US20080219939A1 (en) * | 2007-03-07 | 2008-09-11 | Grune Guerry L | Sunblock formulations |
US20080219938A1 (en) * | 2007-03-07 | 2008-09-11 | Grune Guerry L | SPF compositions |
WO2008109138A1 (en) * | 2007-03-07 | 2008-09-12 | Grune Guerry L | Spf compositions |
WO2008109182A1 (en) * | 2007-03-07 | 2008-09-12 | Grune Guerry L | Sunblock formulations |
US9095522B2 (en) * | 2007-03-19 | 2015-08-04 | Guerry L. Grune | High SPF transparent or translucent, cytoprotective, biodegradable, UV radiation resistant compositions |
EP2501777B1 (en) * | 2009-11-20 | 2022-10-26 | Guerry L. Grune | Broad spectrum uva stable, non-toxic, zinc oxide based complex |
Also Published As
Publication number | Publication date |
---|---|
US20050196361A1 (en) | 2005-09-08 |
US20030031634A1 (en) | 2003-02-13 |
US20060233725A1 (en) | 2006-10-19 |
US6866841B2 (en) | 2005-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050196361A1 (en) | Non endocrine disrupting cytoprotective UV radiation resistant composition | |
US9095522B2 (en) | High SPF transparent or translucent, cytoprotective, biodegradable, UV radiation resistant compositions | |
JP3659959B2 (en) | Composition containing photocatalytic metal oxide and tocopherol and method of using the composition in cosmetics field | |
EP0683662B1 (en) | Waterproof cosmetic or dermatological photoprotective preparations | |
US6274124B1 (en) | Additive for improving the water resistance of cosmetic or dermatological formulations | |
DE69632255T3 (en) | SUNSCREEN | |
US20150110724A1 (en) | High SPF Transparent or Translucent Naturally Derived, Cytoprotective, UV Radiation Resistant Compositions | |
CA2818479C (en) | Broad spectrum uva stable, non-toxic, zinc oxide based complex | |
US6858200B2 (en) | Sunscreen formulations | |
JP2015155474A (en) | Skincare compositions | |
EP2234675A1 (en) | Enhanced photostability of avobenzone in the presence of zinc oxide using phosphate-based emulsifiers | |
US9782610B2 (en) | Nontoxic, non-endocrine disrupting, cytoprotective, UV-radiation resistant sunblock compositions | |
US6540986B2 (en) | Sunscreen compositions | |
US20100028276A1 (en) | Sunscreen compositions | |
WO2008136889A1 (en) | High spf transparent or translucent, cytoprotective, biodegradable, uv radiation resistant compositions | |
JP3518218B2 (en) | Oil-in-water skin external preparation | |
EP1608331B1 (en) | Sunscreen composition comprising a mixture of silicas | |
JPH08283120A (en) | Cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006233725 Country of ref document: US Ref document number: 10485989 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10485989 Country of ref document: US |